Loading
Advesya develops treatments aimed at IL-1RAP, a protein found on leukaemia cells. Its lead treatment, a CAR-T therapy made from the patient's own immune cells, is being tested in acute myeloid leukaemia that has come back or not responded.
Advesya is a French and Swiss clinical-stage biotech company founded in 2020, according to the company, as a spin-out from the French Blood Institute (EFS) in Besançon by Christophe Ferrand and Marina Deschamps, and seeded by Jeito in 2022. Its work targets IL-1RAP, an antigen it describes as upregulated in several cancers and autoimmune conditions. CCTx-001 is an IL-1RAP-directed autologous CAR-T therapy built from CD8 and CD4 T cells, assessed in a phase 1/2 adaptive trial in relapsed or refractory acute myeloid leukaemia (NCT06281847) with sites listed in France, Germany, Spain and Sweden. ADV-101 is a first-in-class ADC made of a humanised IgG1 anti-IL-1RAP antibody carrying a topoisomerase I inhibitor payload through a cleavable linker. Its first registered cancer trial, NCT06281847, was posted on ClinicalTrials.gov in February 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/